ClinicalTrials.gg
RecruitingNCT07938918PEARL 1Updated Nov 16, 2026

Non-Invasive Screening for Embryo Chromosome Abnormalities Using Growth Patterns and Culture Fluid Analysis

An observational study in Aneuploidy, PGT-A and Chromosomal Abnormalities, sponsored by Fakih IVF Fertility Center. Recruiting at 1 site in United Arab Emirates. Open to participants aged 21 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Fakih IVF Fertility Center · Observational

How we know

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
21 Years to 40 Years
Sex
All
01

Study summary

For Couples undergoing in vitro fertilization (IVF), one of the most important decisions is choosing which embryo has the best chance of leading to a healthy pregnancy. Today, this often relies on a biopsy, where a few cells are removed from the embryo for genetic testing (PGT-A). This technique has shown high accuracy; however, this test is invasive, adds cost, and involves handling the embryo directly.

The Prediction of Embryo Aneuploidy using Non-invasive Morphokinetics and Culture Media Readouts (PEARL) Trial is testing a non-invasive alternative that combines two approaches. The first; time-lapse imaging using a camera-equipped incubator to continuously record how an embryo divides and grows, without ever removing it from its stable environment. The second; spent culture media testing by analyzing the fluid that the embryo grows in for biological signals (DNA fragments, microRNA, proteins, and metabolic byproducts) which the embryo releases as it develops.

By studying these two sources of information together, alongside each embryo's actual genetic result from standard PGT-A testing, we aim to find out whether imaging and fluid analysis, combined, can reliably predict whether an embryo is chromosomally normal (euploid) or abnormal (aneuploid) without needing a biopsy.

Taking part does not change a couple's standard IVF treatment. Embryos are cultured and tested exactly as they normally would be; the only difference is that imaging data and a small sample of fluid that would otherwise be thrown away are collected for research analysis. All embryo selection and transfer decisions continue to be based on the clinic's usual standard of care.

If successful, this approach could make embryo assessment safer, faster, and more affordable reducing the need for invasive testing in IVF, in Abu Dhabi and internationally.

Read the detailed description

Time-lapse imaging (TLI) enables continuous, non-invasive assessment of embryo development. Early cleavage timings (t2, t3), cell cycle durations (cc2, cc3), and synchrony measures (s2, s3) have been associated with developmental competence, while later morphokinetic events; compaction and blastocyst expansion, appear particularly informative for blastocyst quality and may carry signals related to chromosomal status.

In parallel, spent embryo culture media (SECM) studies report that cell-free DNA (cfDNA) fragments, microRNA expression patterns, metabolic profiles, and specific secreted proteins differ between embryos with divergent developmental and genetic outcomes, suggesting SECM as a complementary, non-invasive biomarker source.

However, methodological variability across studies; including inconsistent sample collection timing, inadequate contamination control, and heterogeneous assay platforms, limits reproducibility and has constrained clinical translation. Critically, no adequately powered, prospective study has yet integrated detailed morphokinetic profiling with multi-omic SECM assessment and validated the combined approach against preimplantation genetic testing for aneuploidy (PGT-A) as a reference standard.

The PEARL Trial addresses this gap through a large, prospective, standardized dataset combining TLI-derived morphokinetic parameters with multi-omic SECM analysis (cfDNA, microRNA, metabolomic, and proteomic markers), collected under controlled conditions to minimize pre-analytical variability. All embryos will undergo routine PGT-A per standard clinical protocol, providing ground-truth ploidy status against which combined predictive models will be evaluated.

The primary objective is to determine the correlation between integrated morphokinetic/SECM signatures and embryo ploidy, and to assess the predictive performance of a combined non-invasive model relative to PGT-A. Embryo culture and clinical decision-making will follow standard institutional protocols throughout, with TLI and SECM sampling embedded within existing laboratory workflows to avoid any deviation from standard-of-care embryo handling.

02

Conditions studied

  • Aneuploidy
  • PGT-A
  • Chromosomal Abnormalities

Keywords

  • Aneuploidy
  • PGT-A tested embryos
  • Spent embryo culture media (SECM)
03

In context

Aneuploidy

75 studies on the registry are indexed under Aneuploidy; 12 are open to participants now.

This study's planned enrollment of 200 is below the median of 290 across 40 observational studies indexed under Aneuploidy.

Browse Aneuploidy studies →

Lead sponsor

Fakih IVF Fertility Center is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be selected from IVF patients attending the FAKIH IVF clinic in Abu Dhabi.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women aged 21-40 years undergoing IVF/ICSI cycles at Fakih IVF Centre.
  2. Embryos cultured in validated timelapse incubators to the blastocyst stage or until developmental arrest.
  3. Availability of spent embryo culture media (SECM) samples and preimplantation genetic testing for aneuploidy (PGT-A) results for blastocysts

Exclusion criteria

Exclusion Criteria:

  1. Known parental chromosomal abnormalities identified prior to the IVF cycle.
  2. Missing or contaminated SECM samples for analysis
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Aneuploid Embryos

    Embryo culture spent media collected and frozen, then for embryos which are identified as aneuploid by PGT-A, their frozen spent media and morphokinetics will be analyzed.

    Other: No Intervention: Observational Cohort

Interventions

  • OtherNo Intervention: Observational Cohort

    This is an observation cohort. There are no interventions in this study.

06

What researchers measure

Primary outcomes

  1. miRNA expression profiles

    miRNA expression profiles of spent media from embryo culture.

    Time frame: Day 6 or 7 of embryo culture.

Secondary outcomes

  1. Correlation between spent media analysis and morphokinetics

    Correlation between spent media analysis and morphokinetics in PGT-A confirmed Aneuploid embryos. Spent media harvested within 24 hours of embryo removal from culture media.

    Time frame: Day 6 or 7 of embryo culture.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Chen S, Wang L, Hu Y, Yao Y, Gao F, Chang C, Zhang L, Huang H, Lu D, Xu C. Noninvasive preimplantation genetic testing for aneuploidy using blastocyst spent culture medium may serve as a backup of trophectoderm biopsy in conventional preimplantation genetic testing. BMC Med Genomics. 2025 Feb 21;18(1):34. doi: 10.1186/s12920-025-02106-7. PubMed 39984972 ↗
  • Bracewell-Milnes T, Saso S, Abdalla H, Nikolau D, Norman-Taylor J, Johnson M, Holmes E, Thum MY. Metabolomics as a tool to identify biomarkers to predict and improve outcomes in reproductive medicine: a systematic review. Hum Reprod Update. 2017 Nov 1;23(6):723-736. doi: 10.1093/humupd/dmx023. PubMed 29069503 ↗
  • Kamijo S, Hamatani T, Sasaki H, Suzuki H, Abe A, Inoue O, Iwai M, Ogawa S, Odawara K, Tanaka K, Mikashima M, Suzuki M, Miyado K, Matoba R, Odawara Y, Tanaka M. MicroRNAs secreted by human preimplantation embryos and IVF outcome. Reprod Biol Endocrinol. 2022 Aug 30;20(1):130. doi: 10.1186/s12958-022-00989-0. PubMed 36042522 ↗
  • Li J, Liu Y, Qian Y, Zhang D. Noninvasive preimplantation genetic testing in assisted reproductive technology: current state and future perspectives. J Genet Genomics. 2020 Dec 20;47(12):723-726. doi: 10.1016/j.jgg.2020.11.007. Epub 2021 Jan 26. PubMed 33674238 ↗
  • Vera-Rodriguez M, Diez-Juan A, Jimenez-Almazan J, Martinez S, Navarro R, Peinado V, Mercader A, Meseguer M, Blesa D, Moreno I, Valbuena D, Rubio C, Simon C. Origin and composition of cell-free DNA in spent medium from human embryo culture during preimplantation development. Hum Reprod. 2018 Apr 1;33(4):745-756. doi: 10.1093/humrep/dey028. PubMed 29471395 ↗
  • Kosteria I, Anagnostopoulos AK, Kanaka-Gantenbein C, Chrousos GP, Tsangaris GT. The Use of Proteomics in Assisted Reproduction. In Vivo. 2017 May-Jun;31(3):267-283. doi: 10.21873/invivo.11056. PubMed 28438852 ↗
  • Rosenbluth EM, Shelton DN, Wells LM, Sparks AE, Van Voorhis BJ. Human embryos secrete microRNAs into culture media--a potential biomarker for implantation. Fertil Steril. 2014 May;101(5):1493-500. doi: 10.1016/j.fertnstert.2014.01.058. Epub 2014 Mar 12. PubMed 24786747 ↗
  • Vergouw CG, Kieslinger DC, Kostelijk EH, Botros LL, Schats R, Hompes PG, Sakkas D, Lambalk CB. Day 3 embryo selection by metabolomic profiling of culture medium with near-infrared spectroscopy as an adjunct to morphology: a randomized controlled trial. Hum Reprod. 2012 Aug;27(8):2304-11. doi: 10.1093/humrep/des175. Epub 2012 May 30. PubMed 22647453 ↗
  • Sturmey RG, Hawkhead JA, Barker EA, Leese HJ. DNA damage and metabolic activity in the preimplantation embryo. Hum Reprod. 2009 Jan;24(1):81-91. doi: 10.1093/humrep/den346. Epub 2008 Oct 3. PubMed 18835872 ↗
  • Xin X, Wu S, Xu H, Ma Y, Bao N, Gao M, Han X, Gao S, Zhang S, Zhao X, Qi J, Zhang X, Tan J. Non-invasive prediction of human embryonic ploidy using artificial intelligence: a systematic review and meta-analysis. EClinicalMedicine. 2024 Oct 24;77:102897. doi: 10.1016/j.eclinm.2024.102897. eCollection 2024 Nov. PubMed 39513188 ↗
  • Gimenez C, Conversa L, Murria L, Meseguer M. Time-lapse imaging: Morphokinetic analysis of in vitro fertilization outcomes. Fertil Steril. 2023 Aug;120(2):218-227. doi: 10.1016/j.fertnstert.2023.06.015. Epub 2023 Jun 25. PubMed 37364673 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Nov 25, 2026
Primary completionEst.
Nov 25, 2027
CompletionEst.
Dec 30, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938918
Lead sponsor
Fakih IVF Fertility Center
Collaborators
Al Ain University, Khalifa University for Science and Technology
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 25, 2026 (estimated)
Primary completion
Nov 25, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Dr. Lamiya Mohiyiddeen, MD, FRCOG
Contact
lamiya.mohiyiddeen@fakihivf.com
+971543676002
Fatma Bathawab, PhD
Contact
fatma.bathawab@fakihivf.com
+971585707393
Dr. Michael Fakih, PhD
principal investigator · Fakih IVF Abu Dhabi
Lamiya Mohiyiddeen, MD, FRCOG
principal investigator · Fakih IVF Abu Dhabi
Dr. Yasmin Sajjad, MD, FRCOG, DOWH
principal investigator · Fakih IVF Abu Dhabi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion